On a relative basis, the stock has outperformed the S&P 500 by 6.39% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 0.45% in the last 1 week, and is up 11.04% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock. The stock has recorded a 20-day Moving Average of 3.91% and the 50-Day Moving Average is 8.27%.
ResMed (NYSE:RMD): The stock opened at $65.03 on Friday but the bulls could not build on the opening and the stock topped out at $65.29 for the day. The stock traded down to $64.32 during the day, due to lack of any buying support eventually closed down at $64.80 with a loss of -0.46% for the day. The stock had closed at $65.10 on the previous day. The total traded volume was 1,207,395 shares.
The company Insiders own 2.54% of ResMed shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -15.06% . Institutional Investors own 58.7% of ResMed shares. During last six month period, the net percent change held by insiders has seen a change of -15.5%. In a related news, The Securities and Exchange Commission has divulged that Hollingshead James, officer (President, Americas) of Resmed Inc, had unloaded 2,753 shares at an average price of $65.02 in a transaction dated on July 14, 2016. The total value of the transaction was worth $179,000.
ResMed Inc. is engaged in the development, manufacturing, distribution and marketing of medical products for the diagnosis, treatment and management of respiratory disorders, with a focus on sleep-disordered breathing (SDB). The Company develops various products for SDB and other respiratory disorders, including airflow generators, diagnostic products, mask systems, headgear and other accessories. It produces continuous positive airway pressure, variable positive airway pressure and AutoSet systems for the titration and treatment of SDB. Its products also include S9 Escape, AirSense 10 Elite, AirSense 10 CPAP, S9 VPAP S, S9 VPAP ST, S9 VPAP Adapt, S9 VPAP ST-A, S9 VPAP COPD and AirCurve 10 V Auto, among others. It markets sleep recorders for the diagnosis and titration of SDB in sleep clinics and hospitals. Its products include Quattro FX, Swift FX for Her, Mirage FX for Her, Pixi Pediatric Mask, Quattro FX for Her, Swift FX Bella, Swift FX Nano, AirFit N10 and Apnealink Air.